BMY catalysts
Catalysts and events linked to BMY, newest first.
DateCardAvg 5d
- 2026-10-17Bristol-Myers and J&J compare on valuation, dividend, and patent riskBMY JNJ
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of MixBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surgeBMY
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surgeBMY
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of MixBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of MixBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%BMY
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growthBMY XLV+1.33%
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surgeABBV BMY
- 2026-09-21Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surgeABBV BMY
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS SurgeABBV BMY
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2ABBV BMY
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 RevenueBMY XLV+1.33%
- 2026-08-30Cytokinetics Presents Positive Aficamten Phase Data at ESC Congress 2026BMY CYTK
- 2026-08-30Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis ExpirationBMY
- 2026-08-30Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026BMY CYTK
- 2026-06-12Bristol Myers Squibb Targets $3.5B Savings to Sustain DividendBMY
- 2026-05-31BioNTech, BMS Report Positive Lung Cancer Trial Data.BMY BNTX
- 2026-05-21Bristol Myers Squibb seen as undervalued despite patent cliffs.BMY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.